Experience

Cooley Advises on Keros’ Strategic Review Process, Negotiated Share Repurchase Transactions and Planned Issuer Tender Offer

October 15, 2025

Cooley advised Keros Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its $375 million capital return program, which represents the culmination of Keros’ strategic review process, including its share purchase agreements to repurchase all shares of its common stock beneficially owned by ADAR1 Capital Management and Pontifax Venture Capital and planned tender offer for up to $194 million in value of shares of its common stock.

Read more

Related contacts

Bill Roegge
Partner, New York
Kevin Cooper
Partner, New York
Ryan Sansom
Partner, Boston
Marc Recht
Partner, Boston
Minkyu Park
Special Counsel, New York
Julia Kim
Special Counsel, New York
Kathryn Benvenuti
Associate, New York
Koji Fukumura
Partner, San Diego
Sarah Lightdale
Partner, New York
Craig TenBroeck
Partner, San Diego
Elizabeth Wright
Special Counsel, Boston
Margaux Arntson
Associate
Susan Choy
Associate, New York
Brian P. Golger
Associate, New York
Jill Golub
Associate, New York
Denny Xu
Associate, Boston
Jeffrey J. Tolin
Partner, New York
Reid Hooper
Special Counsel, Washington, DC
Justin Kisner
Special Counsel, San Diego

Related Practices & Industries

InnoCare Pharma and Zenas BioPharma Announce License Agreement

October 8, 2025

Cooley advised InnoCare Pharma, a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing first-in-class and best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide, on its transformational license agreement with Zenas BioPharma, granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
Peter Adams
Partner, San Diego
Aaron Pomeroy
Partner, Colorado
Steve Przesmicki
Partner, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Michael Shen
Special Counsel, Shanghai
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
Jameson Davis
Associate, Boston
Amanda Pacheco
Associate, Palo Alto
Ivy Wang
Associate, Shanghai
Denny Xu
Associate, Boston
Zhijing Yu
Associate, Singapore

Related Practices & Industries

LB Pharmaceuticals Announces $285 Million Upsized IPO

September 12, 2025

Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).

Read more

Related contacts

Brandon W. Fenn
Partner, New York
Div Gupta
Partner, New York
Marc Recht
Partner, Boston
Minkyu Park
Special Counsel, New York
Denny Xu
Associate, Boston
Danbi Kim
Associate, Boston
Ariane A. Andrade
Partner, Chicago
Nathaniel Hearn Jr.
Associate, Chicago
Karun Ahuja
Special Counsel, Chicago
Brandon Lefebvre
Quantitative Analyst, Boston
Stephanie Gentile
Partner, New York
Austin Holt
Partner, Santa Monica
Eileen Marshall
Partner, Washington, DC
Phil Mitchell
Partner, New York
Gerard O'Shea
Partner, New York
David Peinsipp
Partner, San Francisco
Ryan Vann
Partner, Chicago
Francis Wheeler
Senior Counsel, Colorado
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Jessica Koffel
Special Counsel, Brussels
Rebecca Ross
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Chelsea Braun
Associate, Boston
Cara Buchicchio
Associate, New York
David Dalton
Associate, Santa Monica
Vince Flynn
Associate, San Diego
Virat Gupta
Associate, Washington, DC
Wyatt Kernell
Associate, Colorado
Allison Kutner
Associate, New York
Brenna McGuire
Associate, Washington, DC
Sarah Miller
Associate, New York
Jayne M. Munger
Associate, New York
Miles Patton
Associate, New York
Alla Kagan
Paralegal Specialist, San Diego
Cathy Rude
Paralegal Specialist, Boston
Jake Ironfield
Transactional Quantitative Analyst, New York
Brian Mitchell
Transactional Quantitative Analyst, San Diego

Related Practices & Industries

MaxCyte – $202 Million IPO

July 30, 2021

Cooley advised MaxCyte on its $201.8 million initial public offering of 15,525,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. MaxCyte, whose securities now trade on the Nasdaq Global Select Market under the symbol “MXCT,” also trades on the London Stock Exchange under the symbols "MXCT" and "MXCN." MaxCyte is a leading provider of cell-engineering platform technologies. Partners Christian Plaza, Brian Leaf and Claire Keast-Butler led the Cooley team.

Related contacts

Christian Plaza
Partner, Reston
Claire Keast-Butler
Co-Partner in Charge – London, London
Katie Kazem
Partner, Reston
Paul Alexander
Associate, Washington, DC
Div Gupta
Partner, New York
Madison Jones
Partner, Washington, DC
Denny Xu
Associate, Boston

Related Practices & Industries

Verve Therapeutics – $307 Million IPO

June 17, 2021

Cooley advised the underwriters on Verve Therapeutics’ $306.7 million initial public offering of 16,141,157 shares of common stock. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Verve Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol VERV, is a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene-editing medicines. Partners Brent Siler, Div Gupta and Richard Segal led the Cooley team.

Related contacts

Div Gupta
Partner, New York
Richard Segal
Partner, New York
Darah Protas
Partner, Washington, DC
Denny Xu
Associate, Boston

Related Practices & Industries

View more

Admissions and credentials

Massachusetts

People's Republic of China

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.